Special Issue "Probiotics and Prebiotics 2014"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 May 2014)
Prof. Dr. Yasuhiro Koga
Laboratory for Infectious Diseases, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan
Interests: probiotics; prebiotics; bifidobacteria; gnotobiology; helicobacter pylori; stomach; atopic dermatitis; gut-brain axis
Probiotics are defined as live non-pathogenic bacteria that beneficially affect the host by influencing the microbiota of the digestive tract. Prebiotics, that are usually saccharides and fiber, represent a source of energy being metabolized by the intestinal and probiotic microbiota. In the last several decades, a rapid rise in the use of probiotics/prebiotics occurred for prevention and treatment of diseases in medicine, such as diarrhea caused by certain pathogenic bacteria and viruses, Helicobacter pylori infection, and allergies, etc. Rigid evidence supporting the efficacy of probiotics/prebiotics in such clinical uses and mechanical studies are now needed in order to firmly establish them in modern medicine.
You may also be interested in the closed special issue "Probiotics and Prebiotics" (with hyperlink: http://www.mdpi.com/journal/pharmaceuticals/special_issues/probiotics_prebiotics
Prof. Dr. Yasuhiro Koga
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
- prevention of diarrhea caused by pathogenic bacteria and viruses
- Helicobacter pylori infection and complications
- inflammatory bowel diseases
- irritable bowel syndrome
- mucosal immunity
- gut-brain axis
Article: Correlation between the Serum Pepsinogen I Level and the Symptom Degree in Proton Pump Inhibitor-Users Administered with a Probiotic
Pharmaceuticals 2014, 7(7), 754-764; doi:10.3390/ph7070754
Received: 15 April 2014; in revised form: 10 June 2014 / Accepted: 11 June 2014 / Published: 25 June 2014| PDF Full-text (751 KB) | HTML Full-text | XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of Paper: Critical Review
Title: Probiotics and the Overarching Influence on End-Organ Function: A Critical Review
Authors: Luis Vitetta 1,2,3, Rachel Manuel 1, Joyce Zhou 1, Anthony W Linnane 1,2, Sean Hall 1
Affiliations: 1 Medlab, Sydney, Australia.
2 Sydney Medical School, The University of Sydney, Sydney, Australia.
3 School of Medicine, The University of Queensland, Brisbane, Australia.
Abstract: At birth, humans experience an induced pro–inflammatory flux. The mediators of this induced activity are a fleet of bacteria that assault the skin and all mucosal surfaces. Thus, the initiating effects, which eventually provide the infant with an immunological profile, are concordant with immune tissue maturation. These effects occur beneath an emergent immune surveillance system and an antigenic tolerance capability radar. Over time, continuous and regulated interactions with environmental and commensal microbial and viral antigens lead to an adapted and maintained symbiotic state of tolerance, especially in the gastrointestinal tract (GIT), which is the organ site with the largest microbial biomass. However, the perplexing and much debated surprise has been that all microbes need not be targeted for destruction. The advent of sophisticated genomic techniques has led to microbiome studies that have clarified the critical and important biochemical activities that commensal bacteria provide to ensure continued GIT hormesis.
Until recently, the GIT and its associated micro–biometabolome was a neglected factor in chronic disease development and end organ function studies. The contributions of the persistent GIT dysbiotic state (i.e., a condition where there is a gut barrier associated abnormality) have been systematically underestimated. Dysbiosis plausibly explains the origins of the systemic metabolic disorders that are encountered in clinical practice; such disorders may explain the epidemic of chronic diseases.
In this brief review, we build a hypothesis that posits subtle adaptation responses by the GIT microbiome. We believe that environmentally triggered and maintained microbiome perturbations drive an aberrant overload of dysbiosis. Probiotic bacterial strains with specific metabolic properties may assist the GIT microbiota and reduce the metabolic dysfunction of end organs, such as the kidney and the liver. This effect may translate into a useful adjunct clinical treatment approach for patients diagnosed with a metabolic disorder.
Last update: 18 February 2014